Skip to main content

Crohn's & Colitis Congress 2025 Main banner

Controlled Clinical Trials in Humans

Controlled Clinical Trials in Humans

Type here to filter the list

(P030) IMPACT OF IMMUNOGENICITY ON CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MAINTENANCE TREATMENT WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE LIBERTY-UC STUDY

Favorite
(P031) LONG-TERM EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE VIVID-2 OPEN-LABEL EXTENSION STUDY

Favorite
(P032) MATCHING-ADJUSTED INDIRECT COMPARISON ON CLINICAL REMISSION FOR MIRIKIZUMAB AND RISANKIZUMAB MAINTENANCE IN THE TREATMENT OF ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

Favorite
(P033) OPTIMIZED GUT BARRIER PROTEOMIC EXPRESSION AND IMPROVEMENTS IN DISEASE- AND BONE-RELATED BIOMARKERS: OUTCOMES FROM A 180-DAY INTERVENTIONAL TRIAL IN ULCERATIVE COLITIS PATIENTS

Favorite
(P034) A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ALGINATE INTAKE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR ULCERATIVE COLITIS

Favorite
(P035) REAL-WORLD FEASIBILITY AND IMPACT OF DECENTRALIZED TRIAL RECRUITMENT FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE AT THREE ACADEMIC CENTERS

Favorite
(P036) TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH RO7790121 DEMONSTRATES EARLY CLINICAL RESPONSE AND SYMPTOM IMPROVEMENT – RESULTS FROM THE PHASE 2B TUSCANY-2 TRIAL (Posters of Distinction)

Favorite
(P037) TWO-YEAR RESULTS OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION THERAPY - FROM LIBERTY-CD AND LIBERTY-UC (Posters of Distinction)

Favorite